Teva-Handok acquires domestic approval of asthma/COPD therapy
A Handok-Teva’s(CEO Sun-dong Park) asthma and chronic obstructive pulmonary disease(COPD) treatment, Duorespi Spiromax(generic name: budesonide/formoterol) acquired approval from the Ministry of Food and Drug Safety on the 17th.
An inhaler, Duorespi Spiromax features the increased usage conveni...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
